The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Relationship between tumor biomarkers (BM) and efficacy in TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician’s choice (TPC) in HER2-positive advanced breast cancer (BC) previously treated with trastuzumab and lapatinib.
Sung-Bae Kim
Consultant or Advisory Role - Novartis (U)
Research Funding - II Dong Pharmaceuticals; Novartis
Hans Wildiers
Consultant or Advisory Role - Roche
Honoraria - Roche
Ian E. Krop
Consultant or Advisory Role - Roche/Genentech (U)
Research Funding - Roche/Genentech
Abraham C.F. Leung
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Caroline Trudeau
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Ron Yu
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Sanne de Haas
Employment or Leadership Position - Roche
Antonio Gonzalez-Martin
No relevant relationships to disclose